Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
Trial ID or NCT#
NCT00316173
Status
NOT RECRUITING
Purpose
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer. This study may allow researchers to determine the effectiveness of combining HYCAMTIN and CARBOPLATIN.
Official Title
An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 Every 21 Days) HYCAMTIN in Combination With Carboplatin (Day 1 Every 21 Days) as Second-Line Therapy in Subjects With Potentially Platinum-Sensitive Relapsed Ovarian Cancer
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: Yes
Exclusion Criteria:
Investigator(s)
Nelson Teng
Contact us to find out if this trial is right for you.
Contact
Tine Bjornlund
6507259167
View on ClinicalTrials.gov
